Literature DB >> 1355979

Signalling in human tumour infiltrating lymphocytes: the CD28 molecule is functional and is physically associated with the CD45R0 molecule.

M R Zocchi1, A Poggi, F Crosti, S Tongiani, C Rugarli.   

Abstract

The CD28 T cell activation pathway was functional in human tumour infiltrating lymphocytes (TIL) and can induce strong proliferation, lymphokine release and calcium mobilisation. Conversely, TIL responded poorly to stimulation via CD2, and CD28 did not synergise with CD2, which is at variance with that observed using peripheral lymphocytes from the same patients. On stimulation with anti-CD28 the monoclonal antibody, most TILs, which were CD3+, CD28+ and CD45R0+ at the beginning of culture, co-expressed both high (CD45RA) and low (CD45R0) molecular weight isoforms of CD45. CD28 was associated with the CD45R0 isoform at the cell surface of activated TIL, as demonstrated by immunoprecipitation and immunoenzymatic assay. Thus CD28 can substitute for CD3 in TIL leading to the expansion of functional lymphocytes and to the amplification of antitumour immune response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1355979     DOI: 10.1016/0959-8049(92)90108-e

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

Review 1.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

Review 2.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

3.  Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area.

Authors:  B Ostenstad; T Lea; E Schlichting; M Harboe
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

4.  Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.

Authors:  W M Mulder; M J Stukart; M Roos; R A van Lier; J Wagstaff; R J Scheper; E Bloemena
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.